Novavax Stock News

The EU''s drugs agency EMA has started evaluating an application for conditional marketing authorisation for US biotech firm Novavaxs COVID-19 vaccine, Nuvaxovid. If granted, this will be the fifth vaccine authorised in the European Union.

If approved, it would be the fifth Covid jab authorised for use within the EU.

LONDON - The European Union''s drug regulator said it received an application from Novavax to authorize the American biotechnology company''s coronavirus vaccine, a request that

NEW YORK, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a class action lawsuit has been filed against of Novavax, Inc. (Novavax or the Company) (NASDAQ: NVAX) in the United States District Court for the District of Maryland on behalf of those who purchased Novavax common stock between March 2, 2021 and October 19, 2021, inclusive (the Class Period).

SAN DIEGO, Nov. 15, 2021 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that purchasers of Novavax, Inc. (NASDAQ: NVAX) securities between March 2, 2021 and October 19, 2021, inclusive (the "Class Period") have until January 11, 2022 to seek appointment as lead plaintiff in

SAN FRANCISCO, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Hagens Berman urges Novavax, Inc. (NASDAQ: NVAX) investors with significant losses to submit your losses now .

The company reported some good news in an important Asian market.

SEOUL, Nov. 15 (Yonhap) -- South Korea will review local drugmaker SK Bioscience Co.''s request to manufacture and sell Novavax COVID-19 vaccine here, the drug safety agency said Monday. Last year, the affiliate under SK Group signed a deal with the

NEW ORLEANS--(BUSINESS WIRE)--Kahn Swick & Foti, LLC (KSF) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until January 11, 2022 to file lead plaintiff applications in a securities class action lawsuit against Novavax, Inc. (NasdaqGS: NVAX), if they purchased the Companys securities between March 2, 2021 and October 19, 2021, inclusive (the Class Period). This action is pending in the United States District Court for the Dis

(PR-inside.com) NEW YORK, NY / ACCESSWIRE / November 15, 2021 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Novavax, Inc. ("Novavax" or the "Company") (NASDAQ:NVAX) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Novavax between March 2, 2021 and October 19, 2021, inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm''s site: www.bgandg.com/nvax. This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934. The complaint alleges that ..

Covovax has been developed by Novavax and is being manufactured by the Pune-based SII, but is not cleared for emergency use in India.

(RTTNews) - Novavax Inc. (NVAX) said that SK bioscience has summited a biologics license application for NVX-CoV2373, the first protein-based COVID-19 vaccine candidate, to South Korea''s Ministry of Food and Drug Safety. NVX-CoV2373 is Novavax'' recombinant nanoparticle COVID-19 vaccine with Matrix-M adjuvant. In collaboration with Novavax, SK

SK bioscience submits application for NVX-CoV2373, the first protein-based COVID-19 vaccine candidate for BLA, to South Korea''s MFDS GAITHERSBURG, Md., Nov. 15, 2021 /PRNewswire/ -- Novavax, Inc.